Multicentre, Non-controlled, Prospective, Post-Marketing Safety Study Following Long-Term Prophylactic Optivate Treatment in Subjects with Severe Haemophilia A.
Phase of Trial: Phase IV
Latest Information Update: 02 Jul 2019
Price : $35 *
At a glance
- Drugs Factor VIII/von Willebrand factor (Primary)
- Indications Haemophilia A
- Focus Pharmacodynamics
- Sponsors Bio Products Laboratory
- 02 Jul 2019 The trial is discontinued at UK and Poland (End Date: 29 Jun 2017), according to European Clinical Trials Database record.
- 12 Jul 2017 Planned End Date changed from 1 Jan 2018 to 1 Aug 2017.
- 12 Jul 2017 Planned primary completion date changed from 1 Jan 2018 to 1 Jul 2017.